Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) International — Reported Sales Growth (%) (%)
Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A
Latest, Q4 2025
3.3%
Period ended Dec 31, 2025
Change on a year earlier
+12.4 pts
-9.1% in Q4 2024
History
41 quarters
Since Q4 2015
Sources
41
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) International — Reported Sales Growth (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q4 2025 | Dec 31, 2025 | 3.3% | +12.4 pts | SEC Filing (0001628280-26-002982) ↗ |
| Q3 2025 | Sep 30, 2025 | 4.3% | +8.2 pts | SEC Filing (0001628280-25-045049) ↗ |
| Q2 2025 | Jun 30, 2025 | -5.6% | -0.7 pts | SEC Filing (0001628280-25-035135) ↗ |
| Q1 2025 | Mar 31, 2025 | -6.7% | +5.8 pts | SEC Filing (0001628280-25-017924) ↗ |
| Q4 2024 | Dec 31, 2024 | -9.1% | -1.3 pts | SEC Filing (0001628280-25-002092) ↗ |
| Q3 2024 | Sep 30, 2024 | -3.9% | +16.0 pts | SEC Filing (0001628280-24-042893) ↗ |
| Q2 2024 | Jun 30, 2024 | -4.9% | +25.0 pts | SEC Filing (0001628280-24-032182) ↗ |
| Q1 2024 | Mar 31, 2024 | -12.5% | +47.2 pts | SEC Filing (0001628280-24-016497) ↗ |
| Q4 2023 | Dec 31, 2023 | -7.8% | +36.1 pts | SEC Filing (0001628280-24-002009) ↗ |
| Q3 2023 | Sep 30, 2023 | -19.9% | +15.5 pts | SEC Filing (0001628280-23-034544) ↗ |
| Q2 2023 | Jun 30, 2023 | -29.9% | -1.5 pts | SEC Filing (0001628280-23-025156) ↗ |
| Q1 2023 | Mar 31, 2023 | -59.7% | -51.2 pts | SEC Filing (0001628280-23-012020) ↗ |
| Q4 2022 | Dec 31, 2022 | -43.9% | -16.4 pts | SEC Filing (0001628280-23-001516) ↗ |
| Q3 2022 | Sep 30, 2022 | -35.4% | -12.3 pts | SEC Filing (0001628280-22-026588) ↗ |
| Q2 2022 | Jun 30, 2022 | -28.4% | -19.7 pts | SEC Filing (0001104659-22-081006) ↗ |
| Q1 2022 | Mar 31, 2022 | -8.5% | -275.5 pts | SEC Filing (0001104659-22-047560) ↗ |
| Q4 2021 | Dec 31, 2021 | -27.5% | -290.6 pts | SEC Filing (0001104659-22-007648) ↗ |
| Q3 2021 | Sep 30, 2021 | -23.1% | -235.0 pts | SEC Filing (0001104659-21-127874) ↗ |
| Q2 2021 | Jun 30, 2021 | -8.7% | -218.6 pts | SEC Filing (0001104659-21-094680) ↗ |
| Q1 2021 | Mar 31, 2021 | 267.0% | +257.4 pts | SEC Filing (0001104659-21-052205) ↗ |
| Q4 2020 | Dec 31, 2020 | 263.1% | +269.6 pts | SEC Filing (0001104659-21-007942) ↗ |
| Q3 2020 | Sep 30, 2020 | 211.9% | +220.2 pts | SEC Filing (0001104659-20-116611) ↗ |
| Q2 2020 | Jun 30, 2020 | 209.9% | +227.6 pts | SEC Filing (0001104659-20-083929) ↗ |
| Q1 2020 | Mar 31, 2020 | 9.6% | +24.1 pts | SEC Filing (0001104659-20-047187) ↗ |
| Q4 2019 | Dec 31, 2019 | -6.5% | -7.7 pts | SEC Filing (0001104659-20-005717) ↗ |
| Q3 2019 | Sep 30, 2019 | -8.3% | -14.1 pts | SEC Filing (0001104659-19-054283) ↗ |
| Q2 2019 | Jun 30, 2019 | -17.7% | -34.3 pts | SEC Filing (0001104659-19-040664) ↗ |
| Q1 2019 | Mar 31, 2019 | -14.5% | -32.0 pts | SEC Filing (0001104659-19-021809) ↗ |
| Q4 2018 | Dec 31, 2018 | 1.2% | -14.1 pts | SEC Filing (0001104659-19-002848) ↗ |
| Q3 2018 | Sep 30, 2018 | 5.8% | -6.9 pts | SEC Filing (0001104659-18-062380) ↗ |
| Q2 2018 | Jun 30, 2018 | 16.6% | +10.5 pts | SEC Filing (0001104659-18-045642) ↗ |
| Q1 2018 | Mar 31, 2018 | 17.5% | +7.5 pts | SEC Filing (0001104659-18-024701) ↗ |
| Q4 2017 | Dec 31, 2017 | 15.3% | +24.1 pts | SEC Filing (0001104659-18-003691) ↗ |
| Q3 2017 | Sep 30, 2017 | 12.7% | +7.3 pts | SEC Filing (0001104659-17-062667) ↗ |
| Q2 2017 | Jun 30, 2017 | 6.1% | +2.5 pts | SEC Filing (0001104659-17-045904) ↗ |
| Q1 2017 | Mar 31, 2017 | 10.0% | +6.8 pts | SEC Filing (0001104659-17-024344) ↗ |
| Q4 2016 | Dec 31, 2016 | -8.8% | -17.4 pts | SEC Filing (0001104659-17-003920) ↗ |
| Q3 2016 | Sep 30, 2016 | 5.4% | – | SEC Filing (0001104659-16-150813) ↗ |
| Q2 2016 | Jun 30, 2016 | 3.6% | – | SEC Filing (0001104659-16-133433) ↗ |
| Q1 2016 | Mar 31, 2016 | 3.2% | – | SEC Filing (0001104659-16-112689) ↗ |
| Q4 2015 | Dec 31, 2015 | 8.6% | – | SEC Filing (0001104659-16-091861) ↗ |
Cite this data
StockData. (2026). Abbott Laboratories Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) International — Reported Sales Growth (%) (%), quarterly Q4 2015–Q4 2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/dx-mol-leg-yoy-rep-intl
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.